The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Campbell
Steven C
SC
Edward Hines Jr VA Hospital, Hines, Illinois, USA. campbes3@ccf.org
Bhoopalam
Nirmala
N
Moritz
Thomas E
TE
Pandya
Mona
M
Iyer
Padmini
P
Vanveldhuizen
Peter
P
Ellis
Nancy K
NK
Thottapurathu
Lizy
L
Garewal
Harinder
H
Warren
Stuart R
SR
Friedman
Nicholas
N
Reda
Domenic J
DJ
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000517:prevention & control*; D004164:Diphosphonates / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D009919:Orchiectomy; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000628:therapy*; D012720:Severity of Illness Index; D000077211:Zoledronic Acid
D000726:Androgen Antagonists; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D007987:Gonadotropin-Releasing Hormone; D000077211:Zoledronic Acid